Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19

Fig. 3

CVL218 binds to the nucleocapsid protein of SARS-CoV-2 (SARS-CoV-2-N). a–e Kinetic analyses of the binding between SARS-CoV-2-N and the tested drugs, including CVL218 (a), PJ-34 (b), olaparib (c), remdesivir (d), and arbidol (e), measured by a SPR-based Biacore instrument. The derived dissociation constants between SARS-CoV-2-N and the tested drugs (CVL218 and PJ-34) are also shown

Back to article page